David A. Siegel Alpine Immune Sciences, Inc. Transaction History

Two Sigma Advisers, LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.75 - $41.6 $7.18 Million - $16.8 Million	404,700 Added 153.25%	668,775 $26.5 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $153,719 - $363,960	18,000 Added 7.31%	264,075 $5.03 Million
Q3 2023 Nov 14, 2023	BUY	$10.13 - $13.98 $1.62 Million - $2.23 Million	159,700 Added 184.89%	246,075 $2.82 Million
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $310,536 - $540,714	45,400 Added 110.8%	86,375 $887,000
Q1 2023 May 15, 2023	SELL	$7.0 - $8.75 $169,400 - $211,750	-24,200 Reduced 37.13%	40,975 $316,000
Q4 2022 Feb 14, 2023	SELL	$5.45 - $7.35 $17,985 - $24,255	-3,300 Reduced 4.82%	65,175 $479,000
Q3 2022 Nov 14, 2022	SELL	$6.89 - $9.39 $228,059 - $310,809	-33,100 Reduced 32.59%	68,475 $493,000
Q2 2022 Aug 15, 2022	SELL	$6.71 - $9.52 $84,546 - $119,952	-12,600 Reduced 11.04%	101,575 $864,000
Q1 2022 May 16, 2022	BUY	$6.41 - $13.89 $41,024 - $88,896	6,400 Added 5.94%	114,175 $1.02 Million
Q4 2021 Feb 14, 2022	BUY	$10.41 - $13.95 $688,101 - $922,095	66,100 Added 158.61%	107,775 $1.49 Million
Q3 2021 Nov 15, 2021	SELL	$8.19 - $11.31 $225,225 - $311,025	-27,500 Reduced 39.75%	41,675 $445,000
Q2 2021 Aug 16, 2021	SELL	$8.81 - $15.03 $500,408 - $853,704	-56,800 Reduced 45.09%	69,175 $623,000
Q1 2021 May 17, 2021	BUY	$10.02 - $13.92 $232,464 - $322,944	23,200 Added 22.57%	125,975 $1.34 Million
Q4 2020 Feb 16, 2021	BUY	$7.42 - $15.96 $217,406 - $467,628	29,300 Added 39.88%	102,775 $1.3 Million
Q3 2020 Nov 16, 2020	BUY	$7.15 - $11.5 $525,346 - $844,962	73,475 New	73,475 $646,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.